<!DOCTYPE html>
<html class="writer-html5" lang="en" >
<head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
      <link rel="shortcut icon" href="../img/favicon.ico" />
    <title>Hepatology - VLRChat</title>
    <link rel="stylesheet" href="../css/theme.css" />
    <link rel="stylesheet" href="../css/theme_extra.css" />
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/github.min.css" />
    
      <script>
        // Current page data
        var mkdocs_page_name = "Hepatology";
        var mkdocs_page_input_path = "Hepatology.md";
        var mkdocs_page_url = null;
      </script>
    
    <!--[if lt IE 9]>
      <script src="../js/html5shiv.min.js"></script>
    <![endif]-->
      <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
      <script>hljs.highlightAll();</script> 
</head>

<body class="wy-body-for-nav" role="document">

  <div class="wy-grid-for-nav">
    <nav data-toggle="wy-nav-shift" class="wy-nav-side stickynav">
    <div class="wy-side-scroll">
      <div class="wy-side-nav-search">
          <a href=".." class="icon icon-home"> VLRChat
        </a><div role="search">
  <form id ="rtd-search-form" class="wy-form" action="../search.html" method="get">
      <input type="text" name="q" placeholder="Search docs" aria-label="Search docs" title="Type search term here" />
  </form>
</div>
      </div>

      <div class="wy-menu wy-menu-vertical" data-spy="affix" role="navigation" aria-label="Navigation menu">
              <ul>
                <li class="toctree-l1"><a class="reference internal" href="..">About</a>
                </li>
              </ul>
              <ul>
                <li class="toctree-l1"><a class="reference internal" href="../Table%20of%20Contents/">Table of Contents</a>
                </li>
              </ul>
              <p class="caption"><span class="caption-text">Chapters</span></p>
              <ul class="current">
                  <li class="toctree-l1"><a class="reference internal" href="../Anesthesia%20and%20Pain%20Management/">Anesthesia and Pain Management</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Cardiology/">Cardiology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Critical%20Care/">Critical Care</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Dermatology/">Dermatology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Endocrinology/">Endocrinology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Gastroenterology/">Gastroenterology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Geriatrics/">Geriatrics</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Hematology%20and%20Oncology/">Hematology and Oncology</a>
                  </li>
                  <li class="toctree-l1 current"><a class="reference internal current" href="#">Hepatology</a>
    <ul class="current">
    <li class="toctree-l2"><a class="reference internal" href="#cirrhosis-overview">Cirrhosis Overview</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#history">History:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#physical-exam">Physical exam:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#labs">Labs</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#imaging">Imaging:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#liver-biopsy">Liver biopsy:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#lab-abnormalities">Lab abnormalities</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#nutrition">Nutrition:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#immunizations">Immunizations:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#additional-management">Additional Management:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#medication-tips">Medication Tips</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#pain">Pain:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#pruritus">Pruritus:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#anxietyinsomnia">Anxiety/insomnia:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#etoh-withdrawal">EtOH withdrawal:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#liver-transplant-lt-workup">Liver Transplant (LT) Workup</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_1">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#indications-and-contraindications">Indications and Contraindications</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#indications">Indications:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#contraindications">Contraindications*:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_1">Evaluation</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#spontaneous-bacterial-peritonitis-sbp">Spontaneous Bacterial Peritonitis (SBP)</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_2">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_2">Evaluation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_1">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#immediate-treatment">Immediate Treatment:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#prophylaxis">Prophylaxis:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#if-suspicion-is-high-for-secondary-bacterial-peritonitis">If suspicion is high for secondary bacterial peritonitis:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#runyons-criteria-to-distinguish-requires-23-criteria-below-protein-glucose-ldh">Runyon's Criteria to distinguish, requires 2/3 criteria below (protein, glucose, LDH)</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#gastroesophageal-varices-and-hemorrhage">Gastroesophageal Varices and Hemorrhage</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_3">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#variceal-screening">Variceal Screening:</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management-non-bleeding-varices">Management (Non-Bleeding Varices)</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management-bleeding-varices">Management (Bleeding Varices)</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#beta-blocker-dosing-table">Beta-Blocker Dosing Table</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#ascites-and-hepatic-hydrothorax">Ascites and Hepatic Hydrothorax</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#ascites">Ascites</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#background_4">Background</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#evaluation_3">Evaluation</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#other-tests">Other tests:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#management_2">Management</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#refractory-ascites">Refractory Ascites:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#hepatic-encephalopathy-he">Hepatic Encephalopathy (HE)</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#classifications-of-he">Classifications of HE:</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_4">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#asterixis-inability-to-maintain-stable-posture-many-ways-to-assess">Asterixis: inability to maintain stable posture; many ways to assess</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#grading-scale">Grading Scale:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#identify-precipitants">Identify precipitants:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_3">Management</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#aki-hepatorenal-syndrome-hrs">AKI &amp; Hepatorenal Syndrome (HRS)</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_5">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#definitions">Definitions:</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#diagnostic-criteria">Diagnostic Criteria:</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_5">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#step-1-exclude-other-obvious-causes-of-renal-injury-such-as-hypovolemia-or-atn">Step 1: Exclude other obvious causes of renal injury such as hypovolemia or ATN</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#step-2-diuretic-cessationalbumin-challenge">Step 2: Diuretic cessation/albumin challenge</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#step-3-diagnosis-of-hrs">Step 3: Diagnosis of HRS</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_4">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#pharmacologic-therapies-in-order-of-preference">Pharmacologic therapies (in order of preference):</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#rrt">RRT:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#liver-transplant">Liver transplant:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#simultaneous-liver-kidney-transplant">Simultaneous liver-kidney transplant:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#hyponatremia-in-cirrhosis">Hyponatremia in Cirrhosis</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_6">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#pathophysiology">Pathophysiology</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_6">Evaluation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_5">Management</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#transjugular-intrahepatic-portosystemic-shunt-tips">Transjugular Intrahepatic Portosystemic Shunt (TIPS)</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_7">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_7">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#indications-for-tips">Indications for TIPS:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#contraindications-to-tips">Contraindications to TIPS:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#pre-procedure-preparation">Pre-procedure preparation:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management-post-tips">Management Post-TIPS</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#hemodynamic-pressure-measurements-and-goals">Hemodynamic Pressure Measurements and Goals:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#hepatocellular-carcinoma-hcc">Hepatocellular Carcinoma (HCC)</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_8">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_8">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#li-rads-classification">LI-RADS Classification:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_6">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#milan-criteria">Milan criteria:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#locoregional-therapies-pts-with-unresectable-disease-or-who-are-not-surgical-candidates">Locoregional therapies: Pts with unresectable disease, or who are not surgical candidates</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#coagulopathy-in-cirrhosis">Coagulopathy in Cirrhosis</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_9">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_9">Evaluation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_7">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#for-teg-transfusion-recommendations-are-as-follows">For TEG transfusion recommendations are as follows:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#portal-vein-thrombosis-pvt">Portal Vein Thrombosis (PVT)</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_10">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#presentation">Presentation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_10">Evaluation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_8">Management</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#alcohol-associated-hepatitis">Alcohol-associated Hepatitis</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_11">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_11">Evaluation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_9">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#steroids">Steroids:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#mash-and-masld">MASH and MASLD</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_12">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#presentation_1">Presentation:</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_12">Evaluation</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_10">Management</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#additional-information">Additional Information</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#acute-liver-injury-and-failure">Acute Liver Injury and Failure</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#background_13">Background</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#etiology">Etiology</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#drugs-associated-with-liver-injury">Drugs Associated with liver injury:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#hepatocellular-injury-r-factor-5-primary-elevation-of-astalt">Hepatocellular Injury: R factor &gt; 5 (Primary elevation of AST/ALT)</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#cholestatic-injury-r-factor-2-primarily-elevated-alkaline-phosphatase">Cholestatic Injury: R Factor &lt; 2 (Primarily elevated Alkaline phosphatase)</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_13">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#neurologic-exam">Neurologic Exam:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#labs_1">Labs:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#imaging_1">Imaging:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#management_11">Management</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#abcs">ABC's:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#monitoring">Monitoring:</a>
    </li>
        </ul>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#treatment-of-primary-injury">Treatment of Primary Injury</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#treatment-of-secondary-complications">Treatment of Secondary Complications</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#specific-management-by-etiology">Specific Management by Etiology:</a>
    </li>
    <li class="toctree-l3"><a class="reference internal" href="#criteria-for-transplantation">Criteria for Transplantation:</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#a-alf-due-to-acetaminophen">A) ALF due to acetaminophen:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#b-alf-not-due-to-acetaminophen-inr-65-or-3-of-the-5-following-criteria">B) ALF not due to acetaminophen: INR &gt; 6.5 OR 3 of the 5 following criteria:</a>
    </li>
    <li class="toctree-l4"><a class="reference internal" href="#other-predictors-of-poor-prognosis-in-absence-of-transplant">Other predictors of poor prognosis in absence of transplant:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    <li class="toctree-l2"><a class="reference internal" href="#non-invasive-liver-testing-for-liver-disease">Non-Invasive Liver Testing for Liver Disease</a>
        <ul>
    <li class="toctree-l3"><a class="reference internal" href="#evaluation_14">Evaluation</a>
        <ul>
    <li class="toctree-l4"><a class="reference internal" href="#shear-wave-elastography-interpretation">Shear wave elastography interpretation:</a>
    </li>
        </ul>
    </li>
        </ul>
    </li>
    </ul>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Hospital%20Medicine/">Hospital Medicine</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Infectious%20Disease/">Infectious Disease</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Nephrology/">Nephrology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Neurology/">Neurology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Ophthalmology/">Ophthalmology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Outpatient%20Medicine/">Outpatient Medicine</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Palliative%20Care/">Palliative Care</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Physical%20Medicine%20and%20Rehabilitation/">Physical Medicine and Rehabilitation</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Procedures/">Procedures</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Psychiatry/">Psychiatry</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Pulmonology/">Pulmonology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Radiology/">Radiology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Rheumatology/">Rheumatology</a>
                  </li>
                  <li class="toctree-l1"><a class="reference internal" href="../Toxicology/">Toxicology</a>
                  </li>
              </ul>
              <ul>
                <li class="toctree-l1"><a class="reference internal" href="../Appendices/">Appendices</a>
                </li>
              </ul>
      </div>
    </div>
    </nav>

    <section data-toggle="wy-nav-shift" class="wy-nav-content-wrap">
      <nav class="wy-nav-top" role="navigation" aria-label="Mobile navigation menu">
          <i data-toggle="wy-nav-top" class="fa fa-bars"></i>
          <a href="..">VLRChat</a>
        
      </nav>
      <div class="wy-nav-content">
        <div class="rst-content"><div role="navigation" aria-label="breadcrumbs navigation">
  <ul class="wy-breadcrumbs">
    <li><a href=".." class="icon icon-home" aria-label="Docs"></a></li>
          <li class="breadcrumb-item">Chapters</li>
      <li class="breadcrumb-item active">Hepatology</li>
    <li class="wy-breadcrumbs-aside">
    </li>
  </ul>
  <hr/>
</div>
          <div role="main" class="document" itemscope="itemscope" itemtype="http://schema.org/Article">
            <div class="section" itemprop="articleBody">
              
                <h1 id="hepatology">HEPATOLOGY</h1>
<p><strong>Editor:</strong> Vanessa I. Rodriguez, MD<br />
<strong>Reviewed by:</strong> Manhal J. Izzy, MD</p>
<hr />
<h2 id="cirrhosis-overview">Cirrhosis Overview</h2>
<p><strong>Author: Ahmad Yanis</strong></p>
<h3 id="background">Background</h3>
<p><strong>Example 1-liner:</strong> 65yo M with cirrhosis due to HCV decompensated by ascites and HE (MELD 25) who is listed for transplant and followed by Dr. Izzy</p>
<table>
<thead>
<tr>
<th>Cirrhosis due to</th>
<th>Compensated / Decompensated by</th>
<th>MELD-Na</th>
<th>Transplant Status</th>
<th>Followed by</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<ul>
<li>
<p><strong>Etiology of cirrhosis:</strong> HCV&gt;HBV, EtOH, NASH, Wilson's, hemochromatosis, A1AT deficiency, autoimmune hepatitis, PSC, PBC, congestive hepatopathy (right heart failure), medication-induced</p>
</li>
<li>
<p><strong>Complications that cause decompensation:</strong> overt ascites (or hepatic hydrothorax), overt hepatic encephalopathy (HE), esophageal variceal hemorrhage (EVH)</p>
</li>
<li>
<p><strong>Always calculate daily MELD-Na scores</strong> (predicts 3 mo survival based on Tbili, Cr, INR, Na)</p>
</li>
</ul>
<h3 id="evaluation">Evaluation</h3>
<p><strong>Goals:</strong> establish etiology, evaluate/treat complications, determine prognosis, and consider transplant evaluation</p>
<h4 id="history">History:</h4>
<ul>
<li>
<p><strong>Symptoms suggesting decompensation:</strong> confusion, sleep disturbances, abdominal swelling, lower extremity edema, scleral icterus/jaundice, pruritus, easy bruising/bleeding (skin, mouth, GI tract), dyspnea</p>
</li>
<li>
<p><strong>Social history:</strong> EtOH and drug use hx, date of last drink, average # of drinks/day, duration of EtOH use, prior rehab, hx of DUI, if there has been continued EtOH use despite knowledge of liver disease; these factors all impact transplant candidacy</p>
</li>
<li>
<p><strong>Ascites:</strong> compliance with diuretics, compliance with salt restriction, frequency of paracentesis (volume removed, date of last para), h/o SBP, hx of TIPs</p>
</li>
<li>
<p><strong>HE:</strong> compliance with lactulose, # of BMs per day, any potential triggers (see HE section)</p>
</li>
<li>
<p><strong>GIB/EVH:</strong> hematemesis, coffee ground emesis, melena, hematochezia (duration, volume, # of bleeding episodes), last EGD (varices, banding) and colonoscopy, compliance with non-selective BBs</p>
</li>
</ul>
<h4 id="physical-exam">Physical exam:</h4>
<p>asterixis, ascites, edema/anasarca, splenomegaly, muscle wasting, gynecomastia, testicular atrophy, palmar erythema, spider angiomata, scleral icterus/jaundice, petechiae/ecchymoses, caput medusa, Terry's nails</p>
<h4 id="labs">Labs</h4>
<ul>
<li><strong>Initial Workup:</strong> CMP, CBC, Coags, UA, HCV/HBV, Fe studies, PEth</li>
<li><strong>Unless requested by hepatology, defer to outpatient:</strong> AFP, ANA, IgG, A1AT, ceruloplasmin, AMA (PBC), ASMA (AIH), anti-SLA (AIH), anti-LKM (AIH)</li>
</ul>
<h4 id="imaging">Imaging:</h4>
<ul>
<li>Abdominal US with duplex unless done in past 6 months or indication for repeating sooner (concern for new portal vein thrombosis)</li>
<li>For transplant eval, needs triple phase CT A/P (contrasted study, arterial and venous phases) or MRI abdomen with contrast</li>
</ul>
<h4 id="liver-biopsy">Liver biopsy:</h4>
<p>gold standard for cirrhosis diagnosis but is not always needed if clinical presentation, labs, and imaging consistent with cirrhosis</p>
<h3 id="lab-abnormalities">Lab abnormalities</h3>
<ul>
<li><strong>Hyponatremia</strong> (see hyponatremia section below)</li>
<li><strong>Cirrhotic coagulopathy (increased INR):</strong> due to ↓ coagulation factor production</li>
<li><strong>Thrombocytopenia:</strong> due to splenic sequestration, ↓ TPO production</li>
<li><strong>Hypoalbuminemia:</strong> indications for 25% albumin transfusion – SBP (1.5g/kg on day 1, 1g/kg on day 3), LVP (6-8g/L of ascites), HRS (albumin challenge: 1g/kg/day with max 100 g/day x 2 days), hypoNa &lt;125 and refractory to fluid restriction</li>
</ul>
<h3 id="management">Management</h3>
<h4 id="nutrition">Nutrition:</h4>
<ul>
<li>High protein diet, 2g Na restriction (if ascites present)</li>
<li>Consider MVI, folate, thiamine (particularly in pts with EtOH use disorder)</li>
<li>Mediterranean diet for NASH</li>
<li>Fluid restriction if hyponatremic</li>
</ul>
<h4 id="immunizations">Immunizations:</h4>
<p>ensure UTD with HBV/HAV, PPSV23, Prevnar, Flu, COVID-19 vaccines</p>
<h4 id="additional-management">Additional Management:</h4>
<ul>
<li>Consider consulting Addiction Psych and Social Work for pts with EtOH use disorder - can assist with arranging Intensive Outpatient Program (IOP), Alcoholics Anonymous (AA)</li>
<li>General screenings include HCC screening (q6 months), EVH screening (see section below), monitor for other decompensations and treat accordingly, monitor MELD and consider transplant evaluation when &gt;15</li>
<li>Refer to hepatology outpatient</li>
</ul>
<h3 id="medication-tips">Medication Tips</h3>
<h4 id="pain">Pain:</h4>
<p>2g limit Tylenol, No NSAIDs, limit sedating medications especially with HE.
- Tramadol 25-50mg generally safe to use</p>
<h4 id="pruritus">Pruritus:</h4>
<p>Sarna lotion, can spot dose antihistamines. Can discuss with pharmacist/attending about starting sertraline, cholestyramine (interacts with many medications), or rifampin.</p>
<h4 id="anxietyinsomnia">Anxiety/insomnia:</h4>
<p>hydroxyzine, avoid benzodiazepines</p>
<h4 id="etoh-withdrawal">EtOH withdrawal:</h4>
<p>If needed for EtOH withdrawal, use lorazepam (Ativan) instead of chlordiazepoxide (Librium) or diazepam (Valium) due to its shorter half life</p>
<hr />
<h2 id="liver-transplant-lt-workup">Liver Transplant (LT) Workup</h2>
<p><strong>Author: Katelyn Backhaus</strong></p>
<h3 id="background_1">Background</h3>
<ul>
<li><strong>Model for End-stage Liver Disease (MELD-Na) score:</strong> initially developed to predict survival following TIPS placement, though is now used to objectively rank patients in terms of priority for liver transplant (LT)</li>
<li>Factors in total bilirubin, creatinine, INR, and Na.</li>
<li>Exception points given for complications like HCC and hepatopulmonary syndrome (HPS), leading to score in mid to high 20's even if biologic MELD is low</li>
<li>
<p>Highest score lasts for 7 days</p>
</li>
<li>
<p><strong>Listing a pt for LT</strong> is determined by a multidisciplinary transplant committee</p>
</li>
<li>Acute liver failure pts take precedence over decompensated cirrhosis pts for LT</li>
</ul>
<h3 id="indications-and-contraindications">Indications and Contraindications</h3>
<h4 id="indications">Indications:</h4>
<ul>
<li>Cirrhosis with MELD ≥ 15 or evidence of decompensation (ascites, variceal bleed, HE, HPS, portopulmonary HTN)</li>
<li>Acute liver failure</li>
<li>HCC that meets Milan criteria</li>
<li>Pts with early hilar cholangiocarcinoma that meets specific criteria</li>
<li>Other rare diseases (e.g., familial amyloid polyneuropathy or hyperoxaluria)</li>
</ul>
<h4 id="contraindications">Contraindications*:</h4>
<ul>
<li>Ongoing substance abuse (must have documented abstinence ≥ 3 mos) – refer to exception policy in Alcoholic Hepatitis section</li>
<li>Untreated or recurrent malignancy or metastatic disease</li>
<li>Active infection, AIDS (CD4 &lt;200)</li>
<li>Documented history of medical noncompliance</li>
<li>Lack of adequate social support</li>
<li>Anatomic contraindications: chronic cardiac/pulmonary conditions that significantly increase perioperative risk (e.g., severe pulm HTN)</li>
<li>Fulminant hepatic failure with sustained ICP &gt;50mmHg or CPP &lt;40mmHg</li>
<li>Class III Obesity (BMI&gt;40) is a relative contraindication (class 2B)</li>
</ul>
<p>*Advanced age (&gt;70) is not itself a contraindication but candidates &gt;70 should be almost free of comorbidities to be considered</p>
<h3 id="evaluation_1">Evaluation</h3>
<ul>
<li>Abdominal CT (triple phase) or MRI (multiphase with contrast) to evaluate for hepatic malignancy and vascular anatomy</li>
<li><strong>Infectious workup:</strong> TB testing, HIV, RPR, VZV, CMV, EBV, and Hepatitis A, B, and C</li>
<li><strong>Cardiac evaluation:</strong> [see flowchart in physical handbook]</li>
<li>If RVSP &gt; 40mmHg on TTE, then R Heart Catheterization is indicated</li>
<li>PFT's, carotid US</li>
<li>Panorex to identify dental disease; consult OMFS pending results</li>
<li>Appropriate cancer screenings (CXR in all patients, CT Chest in prior/current smokers, colonoscopy, pap smear, mammogram, and PSA if applicable)</li>
<li>DEXA scan (osteoporosis in up to 55% of individuals with cirrhosis)</li>
<li>Certification of completion of intensive outpatient program (IOP) for substance abuse</li>
<li>Evaluation by hepatobiliary surgical team after obtaining cross sectional imaging</li>
<li>Psychosocial evaluation (consult Psychiatry, social work)</li>
<li><strong>Current VUMC policy:</strong> pts should be abstinent from alcohol for no less than 3-6 months, although exceptions may be made for early liver transplant based on a very strict protocol. Discuss exception criteria with attending if suspect patient unlikely to survive hospitalization without transplant</li>
</ul>
<p><strong>Note:</strong> Both living and deceased donor transplants are offered at VUMC. Donor evaluation, however, cannot be started before the potential recipient is deemed a candidate. Of note, should consider possible simultaneous liver-kidney transplantation for 1) CKD &lt;30mL/min after &gt; 90 days of eGFR&lt;60 or 2) AKI dependent on dialysis &gt;8 weeks or if extensive glomerulosclerosis present.</p>
<hr />
<h2 id="spontaneous-bacterial-peritonitis-sbp">Spontaneous Bacterial Peritonitis (SBP)</h2>
<p><strong>Author: Bailey DeCoursey</strong></p>
<h3 id="background_2">Background</h3>
<ul>
<li>Infection of ascitic fluid without evidence of a surgical intra-abdominal source</li>
<li>Present in approximately 1/3 of patients with cirrhosis who are hospitalized</li>
<li><strong>Presentation:</strong> fever, abdominal pain, encephalopathy, renal failure, acidosis, and/or leukocytosis. However, up to one-third of the patients with spontaneous infections may be entirely asymptomatic or present with only encephalopathy and/or AKI</li>
<li><strong>Pathophysiology:</strong> Combination of GI bacterial flora overgrowth, reduced liver protein production (low complement levels), impaired phagocytic cell function leading to inability to clear pathogens</li>
</ul>
<h3 id="evaluation_2">Evaluation</h3>
<ul>
<li>Any pt with cirrhosis and ascites who is admitted should have diagnostic para to r/o SBP. <strong>Delaying paracentesis &gt; 12 hours is associated with a 2.7-fold increase in mortality.</strong></li>
<li>Obtain cell count with diff</li>
<li>Calculate the PMNs: total nucleated cells x % neutrophils.</li>
<li>
<p><strong>PMN &gt; 250 cells is diagnostic of SBP.</strong> If there are greater than 100k RBCs, you should correct for them: for every 250 RBCs, subtract 1 PMN</p>
</li>
<li>
<p>A positive ascitic bacterial culture with PMN &lt;250 is called <strong>bacterascites</strong> and asymptomatic patients with bacterascites should NOT receive antibiotics as it is likely a contaminant (however, repeat paracentesis should be performed to exclude progression to SBP). You will also frequently see <strong>culture-negative SBP</strong> (neutrocytic ascites) which SHOULD be treated (see below).</p>
</li>
</ul>
<h3 id="management_1">Management</h3>
<h4 id="immediate-treatment">Immediate Treatment:</h4>
<ul>
<li><strong>Immediately start empiric antibiotics</strong></li>
<li>Guidelines recommend cefotaxime IV 2gm q8 hours x 5 days, but we commonly use <strong>ceftriaxone IV 2g q24h for 5-7 days</strong> at VUMC and Nashville VA</li>
<li>Most common culprits (E. coli, Klebsiella, streptococcal species, staphylococcal species)</li>
<li>If SBP developed with recent hospital admission (90 days), recent exposure to BSA, diagnosed &gt;48 hours of admission, or with sepsis, should give zosyn +/- vanc if prior infection or positive swab for MRSA. Daptomycin should be added with hx of VRE infection instead of vanc.</li>
<li>
<p>Finally, in patients with current or recent exposure to zosyn consider meropenem for MDR coverage.</p>
</li>
<li>
<p><strong>IV albumin</strong> 1.5 g/kg on day 1 and 1g/kg on day 3</p>
</li>
<li>
<p><strong>NSBB</strong> do not need to be discontinued in patients with SBP unless hypotensive (mean arterial pressure &lt;65mmHg). If stopped, the timing of re-initiation is based on recovery of blood pressure</p>
</li>
<li>
<p><strong>PPI's</strong> ↑ risk for SBP in pts with cirrhosis, and should be reviewed for appropriateness</p>
</li>
<li>
<p><strong>Repeat diagnostic paracentesis</strong> two days after antibiotics initiated</p>
</li>
<li>If &lt;25% decrease in PMNs, antibiotics should be broadened. Consider secondary bacterial peritonitis.</li>
</ul>
<h4 id="prophylaxis">Prophylaxis:</h4>
<ul>
<li><strong>Acute prophylaxis:</strong> Ciprofloxacin 500mg BID (preferred) or Bactrim one DS tablet BID x 5-7 days</li>
<li>
<p>IV ceftriaxone 1g daily is currently the recommended antibiotic in patients with hemorrhage</p>
</li>
<li>
<p><strong>Outpatient lifelong prophylaxis:</strong></p>
</li>
<li>Prior SBP</li>
<li>Ascitic protein &lt;1.5 AND Child Pugh &gt;9 and bilirubin &gt;3 OR Renal dysfunction (Cr &gt;1.2, Na &lt;130, or BUN &gt;25)</li>
<li><strong>Preferred:</strong> Bactrim DS tab daily or ciprofloxacin 500mg daily</li>
<li><strong>Alternatives:</strong> cefdinir 300mg daily, Augmentin 875/125 daily</li>
</ul>
<h4 id="if-suspicion-is-high-for-secondary-bacterial-peritonitis">If suspicion is high for secondary bacterial peritonitis:</h4>
<ul>
<li>Examine serum-ascites albumin gradient (SAAG). SBP develops in pts with portal hypertension, defined by SAAG &gt; 1.1 g/dL. SBP is unlikely if SAAG is &lt; 1.1 g/dL.</li>
<li>While not particularly sensitive, an ascitic leukocyte count of 5-10k should prompt consideration of secondary peritonitis</li>
<li>Amylase from fluid can also be helpful to point towards pancreatic ascites, while bilirubin can indicate gallbladder perforation.</li>
<li>Peritoneal fluid CEA and alkaline phosphatase can additionally help identify hollow viscus injury.</li>
<li>Evaluate with cross-sectional imaging and surgical consultation as appropriate</li>
</ul>
<h4 id="runyons-criteria-to-distinguish-requires-23-criteria-below-protein-glucose-ldh">Runyon's Criteria to distinguish, requires 2/3 criteria below (protein, glucose, LDH)</h4>
<table>
<thead>
<tr>
<th></th>
<th>Spontaneous</th>
<th>Secondary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein (g/dL)</td>
<td>&lt; 1</td>
<td>&gt; 1</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>≥50</td>
<td>&lt; 50</td>
</tr>
<tr>
<td>LDH (U)</td>
<td>Elevated, but &lt; 225</td>
<td>&gt; 225</td>
</tr>
<tr>
<td>Organisms</td>
<td>0-1</td>
<td>Polymicrobial</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="gastroesophageal-varices-and-hemorrhage">Gastroesophageal Varices and Hemorrhage</h2>
<p><strong>Author: H. Anh Richardson</strong></p>
<h3 id="background_3">Background</h3>
<ul>
<li>Varices form due to portosystemic collaterals in the setting of portal HTN</li>
<li>Gastroesophageal varices are present in approximately 50% of patients with cirrhosis and their presence correlates with severity of liver disease</li>
<li>The risk of mortality with esophageal variceal hemorrhage (EVH) can be up to 15-20%</li>
<li>Recurrence occurs in over 60% of patients within 1-2 years of the index event</li>
<li><strong>The most important predictor of hemorrhage is the size of the varices.</strong> Other predictors include decompensated cirrhosis (Child B/C) and endoscopic presence of red wale marks or red spots</li>
</ul>
<h3 id="variceal-screening">Variceal Screening:</h3>
<ul>
<li>Regular screening not required in all patients with cirrhosis though initial EGD at time of cirrhosis diagnosis is recommended. Screening can be omitted in patients without evidence of clinically significant portal hypertension (low liver stiffness on elastography [LSM &lt;20 and platelets &gt;150], repeated TE annually) and in patients at low risk of bleed on NSBB.</li>
<li><strong>Compensated cirrhosis without varices:</strong> EGD q3yr</li>
<li><strong>Compensated cirrhosis with small varices that have not bled:</strong> EGD q2yr (unless on NSBB, then no need for follow-up EGD)</li>
<li><strong>Decompensated cirrhosis:</strong> EGD at time of decompensated and then q1yr</li>
<li><strong>Medium/large varices that have not bled:</strong> NSBB if tolerated (follow up surveillance EGD unnecessary) or EVL, repeated until obliterated with first surveillance EGD 1-3 months after and q 6-12 months to check for recurrence</li>
</ul>
<p>In general, most patients with cirrhosis should be on propranolol or carvedilol (preferred due to intrinsic anti-alpha-1-adrenergic activity and facilitates the release of nitric oxide, induces intrahepatic vasodilation further reducing portal pressure), per new guidelines. Always check with the hep attendings if BB needs to be started.</p>
<h3 id="management-non-bleeding-varices">Management (Non-Bleeding Varices)</h3>
<ul>
<li><strong>Primary ppx</strong> with either NSBB (preferred if tolerated; see table below) or endoscopic variceal ligation (EVL). EVL indicated in patients with high risk of bleeding (medium/large varices, small varices with red wale sign, or decompensated patients with varices of any size).</li>
<li>Carvedilol has greater reduction in portal pressures and is preferred if tolerated (goal 6.25mg BID)</li>
<li>Nadolol (given nightly as portal pressures are highest at night) or propranolol (BID)</li>
<li>
<p>For secondary ppx, initiate ~72hr after acute bleed has resolved and octreotide discontinued</p>
</li>
<li>
<p><strong>Discontinue if:</strong> hypotension (SBP &lt;90), AKI-HRS, SBP, or hyponatremia with refractory ascites</p>
</li>
<li>
<p><strong>Secondary ppx</strong> with both NSBB and EVL</p>
</li>
<li>NSBB are associated with reduced mortality, while EVL is not</li>
</ul>
<p><strong>Of note,</strong> in patients with clinically significant portal HTN but are without varices, there is no evidence to support the use of NSBB to prevent varices formation, but high-level evidence does support use of NSBB (strongest evidence for Carvedilol) in prevention of any decompensation (ascites, variceal hemorrhage, HE) and has a mortality benefit (likely driven by significant reduction in ascites development)</p>
<h3 id="management-bleeding-varices">Management (Bleeding Varices)</h3>
<ul>
<li>Place two large-bore IVs (18G or larger), resuscitate with blood products and albumin. Activate massive transfusion protocol if needed.</li>
<li>Consider intubation if need for emergent EGD, change in mental status, ongoing hematemesis, or inability to protect airway</li>
<li>Start <strong>octreotide</strong> 50 mcg IV bolus followed by continuous infusion of 50 mcg/h, to be continued for at 2-5 days should EVH be confirmed on endoscopy</li>
<li><strong>Ceftriaxone</strong> 1g IV q24h for SBP prophylaxis (reduced mortality), then transition to PO ciprofloxacin for total 7-day course</li>
<li><strong>Consult GI</strong> for upper endoscopy for possible EVL vs sclerotherapy. EGD should be performed within 12 hours of admission.</li>
<li>Consider <strong>balloon tamponade</strong> with Blakemore as temporizing measure before definitive management. Patient must be intubated before placement, and preferably GI should be made aware prior to placement.</li>
<li><strong>No role for the correction of INR,</strong> even in the presence of bleeding as excessive blood products and FFP can increase portal pressures and cause worsening bleeding</li>
<li>Vitamin K can be given w/ ↑ INR, though is unlikely to help in the acute setting</li>
<li>Check TEG and fibrinogen and transfuse based on results</li>
<li>AASLD does not recommend specific platelet targets during variceal hemorrhage</li>
<li>Administer blood products in balanced ratio to avoid transfusion related coagulopathy</li>
</ul>
<h3 id="beta-blocker-dosing-table">Beta-Blocker Dosing Table</h3>
<table>
<thead>
<tr>
<th>Therapy</th>
<th>MOA</th>
<th>Starting dose</th>
<th>Titration</th>
<th>Max dose</th>
<th>Goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol</td>
<td>Decreased cardiac output; caused by decreased heart rate and contractility from beta-1 adrenergic blockade</td>
<td>20–40 mg twice daily</td>
<td>Increase the dose every 2–3 d until treatment goal</td>
<td>Without ascites: 320 mg/day; with ascites: 160 mg/day</td>
<td>HR of 55–60 bpm if tolerated; SBP should be maintained ≥90 mm Hg</td>
</tr>
<tr>
<td>Nadolol</td>
<td>Above plus Splanchnic arterial vasoconstriction; caused by beta-2 blockade leading to unopposed alfa-adrenergic vasoconstriction</td>
<td>20–40 mg at bedtime</td>
<td>Increase the dose every 2–3 d until treatment goal</td>
<td>Without ascites: 160 mg/day; with ascites: 80 mg/day</td>
<td>HR of 55–60 bpm if tolerated; SBP should be maintained ≥90 mm Hg</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>Above plus decreased intrahepatic vascular resistance; caused by anti-alpha-adrenergic activity</td>
<td>6.25 mg once daily</td>
<td>Increase to 6.25 mg twice daily after 3 d</td>
<td>12.5 mg/day (higher doses could be considered for non-hepatic indications)</td>
<td>No HR goal; SBP should be maintained ≥90 mm Hg</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="ascites-and-hepatic-hydrothorax">Ascites and Hepatic Hydrothorax</h2>
<p><strong>Author: Thomas Strobel</strong></p>
<h3 id="ascites">Ascites</h3>
<h4 id="background_4">Background</h4>
<ul>
<li>Associated with a reduction in 5-year survival from 80% to 30%.</li>
<li>Most often due to portal HTN. Less common causes include peritoneal or metastatic cancer, CHF, TB, nephrotic syndrome, Budd-Chiari, sinusoidal obstructive syndrome (S.O.S), or complications from procedures and pancreatitis</li>
</ul>
<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 Ascites</td>
<td>Only seen on imaging</td>
<td>2g Na restriction</td>
</tr>
<tr>
<td>Grade 2 Ascites</td>
<td>Moderate, symmetric abdominal distension</td>
<td>2g Na restriction, diuretics</td>
</tr>
<tr>
<td>Grade 3 Ascites</td>
<td>Marked, tense abdominal distension</td>
<td>LVP + Na restriction, diuretics (unless refractory)</td>
</tr>
</tbody>
</table>
<h4 id="evaluation_3">Evaluation</h4>
<ul>
<li>Bedside ultrasound on admission to confirm presence of ascites</li>
<li><strong>Diagnostic paracentesis</strong> in all pts with ascites on admission mainly to rule out occult SBP</li>
<li><strong>Initial paracentesis</strong> or when cause of ascites is uncertain: ascitic fluid total protein, serum and BF Albumin, cell count w/diff, culture</li>
<li><strong>Subsequent/Serial paracenteses:</strong> cell count w/diff, culture, protein</li>
<li>
<p>Always inoculate culture bottles at bedside</p>
</li>
<li>
<p>Per AASLD guidelines elevated INR and thrombocytopenia (&lt;50K) are not contraindications for paracentesis. Additionally, administration of clotting factors or platelets is not recommended. However, practically our procedure team often looks for INR &lt; 3.5 (IR usually does not care about INR)</p>
</li>
<li>
<p><strong>Serum-ascites albumin gradient (SAAG)</strong> = serum albumin - ascites albumin.</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>Total Protein Ascites (not serum)</th>
<th>SAAG ≥1.1 g/dL (Portal HTN)</th>
<th>SAAG &lt; 1.1 g/dL (Non-portal HTN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 2.5 g/dL</td>
<td>Cirrhosis</td>
<td>Nephrotic Syndrome, Myxedema</td>
</tr>
<tr>
<td>≥2.5 g/dL</td>
<td>Post-hepatic portal HTN: Cardiac Ascites, Budd-Chiari</td>
<td>Malignant Ascites, Pancreatic Ascites, TB</td>
</tr>
</tbody>
</table>
<h4 id="other-tests">Other tests:</h4>
<ul>
<li><strong>Triglycerides:</strong> if fluid is milky</li>
<li><strong>Cytology:</strong> if very concerned for peritoneal carcinomatosis. May need up to 3 separate samples (50ml or more) to be able to detect malignant cells</li>
<li><strong>ADA:</strong> if concern for peritoneal TB</li>
<li><strong>Hematocrit:</strong> For bloody appearing fluid (not just serosanguinous) to rule out hemoperitoneum. There needs to be a recent serum HCT for comparison.</li>
<li><strong>Amylase:</strong> If concerned for pancreatic ascites</li>
<li><strong>Glucose, LDH</strong> if concern about secondary peritonitis</li>
</ul>
<h4 id="management_2">Management</h4>
<ul>
<li><strong>2000mg sodium restriction</strong> per day for all ascites (Grade 1-3)</li>
<li><strong>Diuretics</strong> (spironolactone and typically furosemide)</li>
<li>Start at 100mg of spironolactone with up titration to 400mg</li>
<li>Furosemide is added if insufficient diuresis or if limited by hyperkalemia. Use more loop diuretics in patients with CKD.</li>
<li>If Urine Na:K ratio &lt;1, indicates insufficient natriuresis. Can ↑ doses to a max of 400:160</li>
<li>If poor response can change to torsemide 10mg and ↑ to 40mg max (per single dose)</li>
<li>
<p>Fluid restriction usually not necessary unless serum sodium &lt;125 mmol/L</p>
</li>
<li>
<p><strong>Large volume paracentesis</strong> should be performed for tense ascites regardless of serum Cr. Pts with tense ascites should be tapped dry with each paracentesis (per EASL) and may consider an upper limit of 8 L (per AASLD, based on one study)</p>
</li>
<li>
<p>Give 6-8g of albumin per liter of ascites removed, even if &lt; 5L</p>
</li>
<li>
<p>Target weight loss of 0.5 kg/day when diuresing to avoid renal injury</p>
</li>
<li>Discontinue NSAIDs and ACEI/ARB</li>
</ul>
<h4 id="refractory-ascites">Refractory Ascites:</h4>
<p>Two distinctions:
- <strong>Diuretic-resistant:</strong> lack of response to diuretics (max spironolactone 400mg/Lasix 160mg), Na restriction and rapid recurrence following paracentesis
- <strong>Diuretic-intractable:</strong> unable to tolerate diuretic therapy due to adverse drug effects (unexplained HE, AKI, K abnormalities, hypoNa, intractable muscle cramps)</p>
<p><strong>Management aside from liver transplant:</strong>
- Discontinue diuretics once refractory ascites has been established, but continue Na dietary restriction
- Consider oral midodrine; can be especially helpful if pt is also hypotensive
- Serial paracenteses, generally arranged OP with IR
- Consider TIPS (trans jugular intrahepatic portosystemic shunt; has survival benefit) for refractory ascites or recurrent ascites (&gt;3 LVPs in one year despite compliance with diet and diuretics). Following TIPS, cessation or decrease in ascites should occur in ~6 weeks
- Consider discontinuing beta blockers in patients with refractory ascites if sBP &lt;90, SCr &gt;1.5, or Na &lt;130</p>
<hr />
<h2 id="hepatic-encephalopathy-he">Hepatic Encephalopathy (HE)</h2>
<p><strong>Author: Ahmad Yanis</strong></p>
<h3 id="classifications-of-he">Classifications of HE:</h3>
<ul>
<li><strong>Type A:</strong> in patients with acute liver failure</li>
<li><strong>Type B:</strong> in patients with portosystemic shunt without significant liver disease</li>
<li><strong>Type C:</strong> in patients with cirrhosis</li>
<li><strong>Covert HE:</strong> minor or no signs/symptoms but abnormalities on neuropsychological and/or neurophysiological tests</li>
<li><strong>Overt HE:</strong> Clinically appreciable change In mental status (e.g., AxOx2 or asterixis) recurrent (≥ 2 bouts) within 6 months</li>
<li><strong>Persistent:</strong> if the patient does not return to their baseline performance between bouts.</li>
</ul>
<h3 id="evaluation_4">Evaluation</h3>
<h4 id="asterixis-inability-to-maintain-stable-posture-many-ways-to-assess">Asterixis: inability to maintain stable posture; many ways to assess</h4>
<ul>
<li>Check for clonus</li>
<li>Have pt "hold out hands like you are stopping traffic" (if following commands)</li>
<li>Shine light in pupil (look up video of hippus)</li>
</ul>
<h4 id="grading-scale">Grading Scale:</h4>
<table>
<thead>
<tr>
<th>Grade</th>
<th>Behavior Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Mild confusion, changes in behavior, increased sleep, no asterixis, cannot be confirmed without neuropsych testing</td>
</tr>
<tr>
<td>II</td>
<td>Moderate confusion, lethargic, AAOx2, +asterixis</td>
</tr>
<tr>
<td>III</td>
<td>Marked confusion, arousable but falls asleep, incoherent speech, AAOx1, +asterixis</td>
</tr>
<tr>
<td>IV</td>
<td>Coma</td>
</tr>
</tbody>
</table>
<h4 id="identify-precipitants">Identify precipitants:</h4>
<ul>
<li>Infection (rule out SBP in addition to CXR, BCx, UA/Cx)</li>
<li>Medication non-adherence (lactulose)</li>
<li>GI bleed (perform rectal exam and observe Hgb trend)</li>
<li>Over-diuresis resulting in dehydration, electrolyte abnormalities (especially hypoK)</li>
<li>Sedatives/benzo/opiate administration (UDS)</li>
<li>Brain imaging does not provide any diagnostic value for HE but may be utilized if diagnostic uncertainty exists</li>
</ul>
<p>Increased ammonia (NH3) levels do not add any diagnostic, staging, or prognostic value in patients with CLD. A normal ammonia level, however, calls for diagnostic re-evaluation</p>
<p>Arterial NH3 is used in acute liver failure for prognostication (not for management)</p>
<h3 id="management_3">Management</h3>
<ul>
<li>Always determine precipitant and treat underlying condition</li>
<li><strong>Lactulose</strong> 30mL TID initially titrated to 2-3 BMs/D as secondary prophylaxis after the management of first episode of overt HE.</li>
<li>Titrate dose to at least 4 BMs daily, avoid excessive stool output which may exacerbate HE d/t dehydration and electrolyte abnormalities</li>
<li>Consider lactulose enemas vs DHT placement if pt unable to tolerate PO<ul>
<li>DHT are not contraindicated in patients with esophageal varices, but should be avoided in patients with recent hemorrhage or banding</li>
</ul>
</li>
<li>Add <strong>Rifaximin</strong> after the second episode of HE, or if failure to respond to lactulose<ul>
<li>Frequently requires prior authorization for outpatient approval and is expensive</li>
</ul>
</li>
<li>
<p>Consider the addition of golytely as it has been found in RCTs to expedite resolution of severe HE by 1 day</p>
</li>
<li>
<p>Lactulose is generally continued indefinitely after first episode of HE, though discontinuation can be considered on an individual basis if predisposing factors (recurrent infection, EVH, EtOH use) have resolved, improvement in liver function, and improvement in nutritional status</p>
</li>
<li>
<p>For patients with chronic diarrhea off lactulose, consider adding BCAA (0.25 gm/kg/d)</p>
</li>
</ul>
<hr />
<h2 id="aki-hepatorenal-syndrome-hrs">AKI &amp; Hepatorenal Syndrome (HRS)</h2>
<p><strong>Author: Garren Montgomery</strong></p>
<h3 id="background_5">Background</h3>
<ul>
<li>Portal HTN causes shear stress on portal vessels → endothelium release of vasodilators → splanchnic vasodilation and reduced effective blood volume (decreased MAP) → RAAS activation → sodium and water retention and severe renal vasoconstriction</li>
<li>Bacterial translocation (as seen in SBP) increased circulating pro-inflammatory cytokines → splanchnic vasodilation</li>
</ul>
<h3 id="definitions">Definitions:</h3>
<ul>
<li>
<p><strong>HRS-AKI</strong> (formerly type I HRS): Rise in Cr ≥0.3 within 48h, rise in Cr ≥50% within 7 days, OR UOP &lt;0.5 mL/kg/hr for 6 hours</p>
</li>
<li>
<p><strong>HRS-NAKI ("non-AKI")</strong> (formerly type II HRS):</p>
</li>
<li><strong>HRS-AKD:</strong> eGFR&lt;60 for &lt;3 months in absence of other structural causes OR % rise in Cr ≤50% using last available Cr over last 3 months as baseline</li>
<li><strong>HRS-CKD:</strong> eGFR&lt;60 for ≥3 months in absence of other structural causes</li>
</ul>
<h3 id="diagnostic-criteria">Diagnostic Criteria:</h3>
<ul>
<li>Diagnosis of AKI (see above) without other cause (see below)</li>
<li>No response or inadequate response at 48 hrs after volume expansion with albumin (1g/kg/day) and withdrawal of diuretics</li>
<li>Absence of proteinuria (&lt;500 mg/d), absence of hematuria (&lt;50 RBCs per HPF), normal renal ultrasound (exclude if patient has known CKD)</li>
<li>Suggestion of renal vasoconstriction with FeNa &lt;0.2, FeUrea &lt;20 (most sensitive diagnostic measure). UNa &lt;20 is suggestive but not diagnostic given baseline sodium avidity in cirrhosis and inability to calculate FeNa. If UNa Is &lt;20, FeNa cannot be calculated.</li>
<li>Cut off for ATN in cirrhosis is a FeNa &gt;0.5, rather than 1 in the general population</li>
</ul>
<h3 id="evaluation_5">Evaluation</h3>
<h4 id="step-1-exclude-other-obvious-causes-of-renal-injury-such-as-hypovolemia-or-atn">Step 1: Exclude other obvious causes of renal injury such as hypovolemia or ATN</h4>
<ul>
<li>Common precipitants of AKI: infection, over diuresis, GI bleeding, recent LVP without subsequent volume expansion, nephrotoxic drugs/NSAIDs</li>
<li><strong>Workup:</strong> BMP, UA with microscopy, urine electrolytes (FeNa, FeUrea), urine protein/Cr ratio, renal ultrasound (to assess for chronicity), diagnostic para to rule out SBP</li>
</ul>
<h4 id="step-2-diuretic-cessationalbumin-challenge">Step 2: Diuretic cessation/albumin challenge</h4>
<ul>
<li><strong>STOP</strong> all diuretics, beta blockers, NSAIDs, ACE/ARBs, anti-hypertensives, vasodilators, nephrotoxins</li>
<li><strong>START</strong> volume expansion with albumin 1g/kg/day (up to a max of 100 g/day) x2 days</li>
</ul>
<h4 id="step-3-diagnosis-of-hrs">Step 3: Diagnosis of HRS</h4>
<ul>
<li>If no other clear cause of AKI is identified and SCr has not improved after 48 hours of diuretic cessation and volume expansion, proceed promptly to vasopressor treatment</li>
</ul>
<h3 id="management_4">Management</h3>
<h4 id="pharmacologic-therapies-in-order-of-preference">Pharmacologic therapies (in order of preference):</h4>
<ul>
<li>
<p><strong>Terlipressin</strong> (+/- albumin 50g/day, unless there is evidence of volume overload). Most effective medication based on randomized clinical trials, NOW FDA APPROVED and approved for use at VUMC in Transplant Candidates only. Titration is done based on creatinine response.</p>
</li>
<li>
<p><strong>Alternatively, consider Norepinephrine</strong> (+/- albumin 50 g/day)</p>
</li>
<li>Requires central access (PICC vs triple lumen) but can be administered on stepdown unit</li>
<li>Guidelines recommend NE to be dosed at 0.5-3 mg/hr. Would ask fellow, attending or pharmacist for baseline. VUMC protocol for ICU and stepdown:</li>
<li>
<p>Start NE gtt at 3mcg/min. If UOP is &lt;200 or MAP &lt;10mm Hg from baseline, increase by 3 mcg/min every 4 hours</p>
</li>
<li>
<p>Continue to hold diuretics. LVP is still generally considered safe even in HRS if indicated by tense ascites (account for albumin repletion from LVP and HRS protocol). This can be attending specific and would confirm prior to performing</p>
</li>
<li>
<p>Therapy is generally continued until HRS is reversed or the hepatology attending deems it refractory to medical treatment. (Per guidelines, protocol normally discontinued if Cr remains at pretreatment level or above &gt;4 days)</p>
</li>
<li>
<p>Patients with HRS-NAKI (formerly type II HRS) may respond to the above therapies, but recurrence of renal dysfunction after withdrawal of vasoconstrictors is the norm and thus current guidelines do not recommend them for this scenario</p>
</li>
</ul>
<h4 id="rrt">RRT:</h4>
<p>Dialysis can be considered for those who fail to respond to pharmacologic therapy, particularly as a bridge to liver transplant. Decision to initiate should be individualized</p>
<h4 id="liver-transplant">Liver transplant:</h4>
<p>The best and most definitive treatment regardless of response to pharmacologic therapy</p>
<h4 id="simultaneous-liver-kidney-transplant">Simultaneous liver-kidney transplant:</h4>
<ul>
<li>HRS often resolves with LT alone. Indications for kidney transplant are usually for patients with severe chronic renal dysfunction or on RRT. Must consult transplant nephrology.</li>
</ul>
<p><strong>Criteria for SLKT:</strong>
- eGFR &lt;60 for &gt;30 days AND latest eGFR &lt;30
- eGFR &lt;25 for &gt;6 consecutive weeks with a documented eGFR q7 days
- Metabolic kidney disease and polycystic disease</p>
<ul>
<li>Can qualify for safety net kidney transplant after liver transplant if eGFR &lt;20 2-12 months post-operatively (would be at higher priority than the rest of the kidney transplant list)</li>
</ul>
<hr />
<h2 id="hyponatremia-in-cirrhosis">Hyponatremia in Cirrhosis</h2>
<p><strong>Author: Kinsley Ojukwu</strong></p>
<h3 id="background_6">Background</h3>
<ul>
<li>Hyponatremia in cirrhosis is often defined as serum Na &lt; 135 mmol/L</li>
<li>Very common problem; prevalence: ~50% of individuals have serum &lt; 135 mmol/L, ~22% &lt; 130 mmol/L</li>
<li>Degree of hyponatremia is associated with progression of cirrhosis; patients with hypona have greater incidence of HE, SBP, and HRS, increased complications &amp; mortality pre/post-tx.</li>
<li>Patients most commonly have hypervolemic (dilutional) hypona.</li>
</ul>
<h3 id="pathophysiology">Pathophysiology</h3>
<ul>
<li><strong>Hypovolemic hyponatremia:</strong> 2/2 excessive diuretic use</li>
<li><strong>Hypervolemic hyponatremia:</strong> Advanced cirrhosis → chronic inflammation and fibrosis in liver → increased resistance to portal flow → portal hypertension → release of vasoactive compounds (primarily nitric oxide) → splanchnic arterial vasodilation → reduced effective arterial blood volume (splanchnic veins contain 20% to 50% of the total blood volume) → reduced effective intravascular volume leads to activation of RAAS + ADH + sympathetic nervous system → RAAS encourages Na retention and ADH causes insertion of aquaporins in distal tubule and collecting duct to increase water reabsorption → dilutional (hypervolemic) hyponatremia</li>
</ul>
<h3 id="evaluation_6">Evaluation</h3>
<ul>
<li>Uosm, Sosm, UNa to rule out competing processes (e.g. beer potomania)</li>
</ul>
<h3 id="management_5">Management</h3>
<ul>
<li>Do not correct Na faster than 6-8mEq/L in 24 hours</li>
<li>Discontinue anti-hypertensives (including beta blockers) in patients with ascites and hypona. Hold diuretics when Na &lt;125</li>
<li>Fluid restriction is recommended only in patients with Na &lt;125. Restriction is generally effective at 1-1.5L and must be less than daily UOP to increase free water excretion</li>
<li>Replete K to 4.0</li>
<li>25% albumin infusion (1g/kg split into BID dosing), has been shown to increase serum Na and have higher rates of hypona resolution at 30 days</li>
<li>Treatment considerations include vasopressors, urea tabs</li>
<li>Vaptans are generally not used in clinical practice given recent RCTs showing harm with use</li>
<li>Salt tabs should not be used to raise serum Na due to worsening hypervolemia</li>
<li>Nephrology should be consulted if not improved after 48 hours</li>
</ul>
<hr />
<h2 id="transjugular-intrahepatic-portosystemic-shunt-tips">Transjugular Intrahepatic Portosystemic Shunt (TIPS)</h2>
<p><strong>Author: Ahmad Yanis</strong></p>
<h3 id="background_7">Background</h3>
<ul>
<li>A TIPS procedure is done by IR to manage sequalae of portal HTN (specifically variceal bleeding and ascites)</li>
<li>A low-resistance shunt is created between an intrahepatic branch of the portal vein and the hepatic vein, allowing blood to bypass the high-resistance vessels within the fibrotic liver.</li>
<li>Ideally, creating the smallest-necessary caliber shunt is desirable. Recent studies suggest that an 8-mm-diameter PTFE-lined TIPS may be sufficient to prevent variceal rebleeding and potentially decrease the incidence of hepatic encephalopathy</li>
</ul>
<h3 id="evaluation_7">Evaluation</h3>
<h4 id="indications-for-tips">Indications for TIPS:</h4>
<ul>
<li><strong>Variceal hemorrhage</strong> (esophageal, gastric, etc.)</li>
<li><strong>Early "preemptive" TIPS</strong> is an urgent TIPS placement within 72 hrs (preferably within 24 hours) of initial endoscopic hemostasis in pts at high risk for rebleeding (Child-Pugh Class B with active bleeding upon insertion of endoscope or Child-Pugh Class C with recent bleeding</li>
<li><strong>"Rescue" TIPS</strong> is placed in pts with active, uncontrolled variceal bleeding or if bleeding recurs despite maximal endoscopic and pharmacologic therapy</li>
<li><strong>Refractory ascites</strong> (prolongs survival)</li>
<li><strong>Other:</strong> bleeding portal hypertensive gastropathy, bleeding gastric varices, PVT recanalization, Budd-Chiari syndrome, hepatic hydrothorax</li>
</ul>
<h4 id="contraindications-to-tips">Contraindications to TIPS:</h4>
<p><strong>Absolute contraindications:</strong>
- Primary prevention of variceal bleeding, congestive heart failure, severe tricuspid regurgitation, severe pulmonary hypertension, multiple hepatic cysts or masses, Sepsis, unrelieved biliary obstruction</p>
<p><strong>Relative contraindications:</strong>
- Hepatic encephalopathy, hepatic tumors (especially if centrally located), thrombocytopenia (&lt;20k), moderate pulmonary hypertension</p>
<h4 id="pre-procedure-preparation">Pre-procedure preparation:</h4>
<ul>
<li><strong>Labs:</strong> CBC, CMP, INR</li>
<li><strong>Liver imaging</strong> to assess portal system patency and exclude liver masses</li>
<li>Ideally triple phase CT with contrast</li>
<li>In pts with renal impairment or active variceal bleeding, RUQ U/S with doppler is acceptable</li>
<li><strong>TTE</strong> to evaluate for evidence of congestive heart failure, pulmonary hypertension, or valvular disease.</li>
<li><strong>Antibiotic ppx</strong> with ceftriaxone 1g IV once at the time of TIPS insertion as enteric bacteria within the static portal system can enter systemic circulation</li>
<li>Patients with HE should receive <strong>rifaximin prophylaxis</strong> starting 2 weeks before procedure and maintained for at least 6 months after the procedure</li>
</ul>
<h3 id="management-post-tips">Management Post-TIPS</h3>
<ul>
<li>Immediately following TIPS, pts are observed in the hospital overnight for complications</li>
<li>
<p>Monitor CBC and vitals closely. If hemodynamically unstable, STAT CBC and low threshold to obtain CTA A/P to evaluate for a bleeding source</p>
</li>
<li>
<p>TIPS causes a substantial increase in venous return to the heart, which can unmask cardiac dysfunction that was previously compensated for</p>
</li>
<li>
<p>Obtain RUQ U/S with Doppler to assess shunt patency 1 month of TIPS placement, or if ascites and/or variceal hemorrhage reoccur</p>
</li>
<li>
<p>If patient with a TIPS develops refractory HE, can consider TIPS revision to lessen HE symptoms</p>
</li>
<li>
<p>Clearance of ascites is not immediate post-TIPS (may take 6-12 weeks), and patients should be maintained on a sodium-restricted diet and diuretics until ascites is adequately controlled.</p>
</li>
</ul>
<h4 id="hemodynamic-pressure-measurements-and-goals">Hemodynamic Pressure Measurements and Goals:</h4>
<ul>
<li>The HVPG refers to the difference in intravascular pressure between the portal vein and the hepatic vein. During TIPS placement, direct portal pressures are measured and used to calculate the portosystemic pressure gradient (PSPG)</li>
<li>In patients with acute, uncontrolled esophageal variceal bleeding, the desired post-TIPS PSPG is &lt;12 mm Hg or, If the former is not feasible, a reduction ≥50% from baseline PSPG</li>
<li>The desired PSPG for secondary prevention of gastroesophageal variceal bleeding is &lt;12 mm Hg</li>
<li>In patients not achieving a PSPG &lt;12 mm Hg despite dilation of the stent to a maximum 10 mm of diameter, the addition of nonselective beta-blockers (NSBBs) should be considered</li>
</ul>
<hr />
<h2 id="hepatocellular-carcinoma-hcc">Hepatocellular Carcinoma (HCC)</h2>
<p><strong>Author: Julie Cui</strong></p>
<h3 id="background_8">Background</h3>
<ul>
<li>Fifth most common tumor and the second most common cause of cancer related death worldwide</li>
<li>The incidence in patients with cirrhosis is 2-4% per year</li>
<li>In chronic HBV and NASH, pts can develop HCC without having cirrhosis</li>
</ul>
<h3 id="evaluation_8">Evaluation</h3>
<ul>
<li><strong>Regular screening</strong> in pts with cirrhosis (or chronic HBV without cirrhosis) for HCC</li>
<li>RUQ U/S q6mo (with or without AFP)</li>
<li>
<p>Routine screening with CT or MRI is not recommended</p>
</li>
<li>
<p><strong>Options If U/S not satisfactory:</strong></p>
</li>
<li>CT A/P w/contrast, in comments specify triple phase for HCC screening</li>
<li>MRI, specify Gadovist (preferred contrast agent)</li>
<li>
<p>Contrast-enhanced ultrasound</p>
</li>
<li>
<p>AFP trend is more useful than one value in time, though AFP &gt;20 should prompt multiphase CT or MRI for further evaluation</p>
</li>
<li>
<p>Diagnosis can be made either by imaging (most common) or biopsy (rare)</p>
</li>
<li>Triple phase CT demonstrates strong early uptake in arterial phase, with subsequent wash-out in portal-venous phase</li>
<li>If diagnosis remains unclear: can surveillance imaging or biopsy</li>
<li>LI-RADS system notes risk of malignancy based on imaging characteristics</li>
</ul>
<h4 id="li-rads-classification">LI-RADS Classification:</h4>
<table>
<thead>
<tr>
<th>LI-RADS</th>
<th>What does it mean?</th>
<th>What do we do?</th>
</tr>
</thead>
<tbody>
<tr>
<td>LR-1 to LR-2</td>
<td>Definitely/probably benign</td>
<td>Routine surveillance, consider diagnostic imaging within 6 mos</td>
</tr>
<tr>
<td>LR-3 to LR-4</td>
<td>Indeterminate/probably HCC</td>
<td>Repeat or alternative diagnostic imaging in 3-6 mos. Consider Bx for LI-RADS 4</td>
</tr>
<tr>
<td>LR-5</td>
<td>Definitely HCC</td>
<td>Plan treatment as noted below</td>
</tr>
<tr>
<td>LR-M</td>
<td>Cancer, but may not be HCC</td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="management_6">Management</h3>
<ul>
<li>Lesions that meet Milan criteria can qualify for MELD exception points and are considered transplant candidates</li>
<li>This accounts for pts with minimal synthetic dysfunction (and therefore low MELD)</li>
</ul>
<h4 id="milan-criteria">Milan criteria:</h4>
<ul>
<li>Single tumor with diameter &gt;2cm but &lt;5 cm, no more than 3 tumors, each &lt;3 cm</li>
<li>
<p>No signs of extra-hepatic involvement or vascular invasion</p>
</li>
<li>
<p><strong>Liver transplant</strong> is definitive treatment, although <strong>resection</strong> can also be curative (favored in pts with early cirrhosis i.e. Child Pugh A)</p>
</li>
</ul>
<h4 id="locoregional-therapies-pts-with-unresectable-disease-or-who-are-not-surgical-candidates">Locoregional therapies: Pts with unresectable disease, or who are not surgical candidates</h4>
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiofrequency ablation</td>
<td>If in a favorable location and size, IR can percutaneously ablate with a large needle that emits microwave frequencies</td>
</tr>
<tr>
<td>Trans-arterial chemoembolization (TACE)</td>
<td>Chemotherapeutic agents injected into the tumor to occlude the feeding artery to the area.</td>
</tr>
<tr>
<td>Trans-arterial radioembolization (TARE)</td>
<td>Like TACE, though radioactive compound (i.e. Y-90) is Injected In the the feeding artery</td>
</tr>
<tr>
<td>Stereotactic body Radiation Therapy (SBRT)</td>
<td>Radiation therapy: can be used as an alternative to ablation or trans-arterial therapy</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>For metastatic disease</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="coagulopathy-in-cirrhosis">Coagulopathy in Cirrhosis</h2>
<p><strong>Author: John Laurenzano</strong></p>
<h3 id="background_9">Background</h3>
<ul>
<li>The liver is responsible for production of both pro- (factor II, V, VII, IV, X, and XI) and anti-coagulants (protein C, S) in hemostasis. Factor VIII is the only one not made by the liver.</li>
<li>Thrombocytopenia is caused by splenic sequestration from portal HTN, failure to produce thrombopoietin (TPO), and bone marrow failure</li>
<li>Hemostatic changes in cirrhotics are incredibly complex, as they involve both procoagulant and anticoagulants. The current thought is that cirrhosis is NO LONGER considered a condition associated with an overall increased bleeding tendency, as the pro-hemostatic and anti-hemostatic pathways are deranged in a way that counterbalance each other.</li>
</ul>
<h3 id="evaluation_9">Evaluation</h3>
<ul>
<li>INR/PT, and PTT are poorly reflective of bleeding risk</li>
</ul>
<h3 id="management_7">Management</h3>
<ul>
<li><strong>Pre-procedural FFP is not recommended,</strong> as it has potential harm w/o proven benefit</li>
<li>
<p><strong>Low risk procedures</strong> (i.e., paracentesis) do not require pre-procedural blood products and per guidelines there is no established INR or platelet cut off</p>
</li>
<li>
<p><strong>In bleeding pts,</strong> the following are recommended per AASLD and AGA guidelines</p>
</li>
<li>IV Vitamin K 10mg x 3 days</li>
<li><strong>FFP:</strong> Not recommended, unless as part of a balanced transfusion effort to avoid transfusion related coagulopathy, or if a TEG screen suggests potential benefit</li>
<li><strong>Cryoprecipitate:</strong> if fibrinogen &lt; 120</li>
<li>
<p><strong>Platelets:</strong> No specific targets regardless of bleeding. Pre-procedurally, recommend &gt;50</p>
</li>
<li>
<p><strong>Appropriate DVT ppx</strong> should be given with few exceptions (plts &lt;50k, active hemorrhage)</p>
</li>
</ul>
<h4 id="for-teg-transfusion-recommendations-are-as-follows">For TEG transfusion recommendations are as follows:</h4>
<ul>
<li>10 mg/kg FFP if R-time &gt;10 minutes</li>
<li>1u Plts if maximum amplitude &lt;55 mm</li>
<li>5u cryo if alpha angle &lt;45</li>
</ul>
<hr />
<h2 id="portal-vein-thrombosis-pvt">Portal Vein Thrombosis (PVT)</h2>
<p><strong>Author: Pakinam Mekki</strong></p>
<h3 id="background_10">Background</h3>
<ul>
<li>Portal Vein Thrombosis (PVT) can worsen decompensation (i.e. variceal hemorrhage), however, worsening portal HTN → more sluggish flow → increased risk PVT</li>
</ul>
<h3 id="presentation">Presentation</h3>
<ul>
<li>Often identified asymptomatically on U/S, but can be identified by new or worsening decompensation of portal HTN</li>
<li>Variceal hemorrhage is the most common decompensating event associated with PVT</li>
<li>Intestinal ischemia (abdominal pain, hematochezia) from PVT is exceedingly rare but associated with significant morbidity/mortality</li>
</ul>
<h3 id="evaluation_10">Evaluation</h3>
<ul>
<li><strong>RUQ U/S with doppler</strong></li>
<li>
<p>Once identified, should be further assessed with triple phase CT or MRI with Gadovist contrast to exclude HCC with tumor thrombus</p>
</li>
<li>
<p>Pts with newly identified PVT should undergo EGD to evaluate for high-risk varices, both for diagnostic and therapeutic considerations</p>
</li>
<li>
<p>PVT in pts without cirrhosis should prompt evaluation for hypercoagulable disorders</p>
</li>
</ul>
<h3 id="management_8">Management</h3>
<ul>
<li>Start AC if acute thrombus occludes &gt;50% of main portal vein, &lt;50% but extends into SMV, thrombus is symptomatic, or patient is a transplant candidate (irrespective of size). Requires discussion with attending/transplant team.</li>
<li>AC options: warfarin, LMWH, or DOAC</li>
<li>
<p>DOAC's are safe in Childs Class A, can be used with caution in Childs B, and are contraindicated in Childs C</p>
</li>
<li>
<p>Pts with chronic occlusive PVT (&gt;6 mos) or with cavernous transformation with collaterals do not generally benefit from AC</p>
</li>
<li>
<p>Pts with high-risk varices should undergo endoscopic management or be on NSBB for prophylaxis for variceal hemorrhage, as noted above</p>
</li>
<li>
<p><strong>TIPS with portal vein recanalization</strong> has recently emerged as a therapeutic modality for PVT in LT candidates to allow for anastomosis, in patient's with chronic PVT and recurrent bleeding/refractory ascites, or in patients whom intestinal ischemia persists despite AC.</p>
</li>
<li>
<p>Pts should undergo follow up intermittently with US to assess for recanalization. AC may be stopped if there is failure to recanalize.</p>
</li>
<li>
<p>If pts are not candidates for AC, they'll simply be treated for complications of portal HTN</p>
</li>
</ul>
<hr />
<h2 id="alcohol-associated-hepatitis">Alcohol-associated Hepatitis</h2>
<p><strong>Author: Ahmad Yanis</strong></p>
<h3 id="background_11">Background</h3>
<ul>
<li>Acute onset of rapidly progressive jaundice (within prior 8 weeks) in pt with heavy EtOH intake (&gt;40g in females or &gt;60g in males EtOH/day for &gt;6 mos, or within &lt;60 days of abstinence)</li>
<li>May present after they have quit drinking due to immunosuppressive effects of alcohol</li>
<li><strong>Risk Factors:</strong> Female, Hispanic ethnicity, binge drinking, poor nutrition, and obesity</li>
</ul>
<h3 id="evaluation_11">Evaluation</h3>
<ul>
<li>AST &gt;60, AST/ALT &gt;1.5, both values &lt;400 IU/L; TBili &gt;3.0 mg/dL, documentation of heavy EtOH use until 8 weeks prior to presentation (some guidelines state 12 weeks)</li>
<li><strong>Prognostication with Maddrey's Discriminant Function:</strong> 4.6 * (PTpt – PTctrl) + Tbili</li>
<li>Maddrey &gt; 32 or MELD &gt; 20 = poor 30d prognosis &amp; may benefit from steroids (see below)</li>
<li>RUQ U/S to rule out obstructive cause of jaundice</li>
<li>Biopsy is not typically required but will show neutrophilic lobular inflammation, hepatocyte ballooning, steatosis, and pericellular fibrosis.</li>
<li><strong>Phosphatidylethanol (PEth) level</strong> is a biomarker of ethanol consumption over ~ 4wks; &gt;20 ng/mL can indicate chronic moderate/heavy alcohol intake</li>
<li>A single episode consumption can result in detectable Peth for up to 12 days. Can be elevated for months with regular heavy alcohol intake</li>
<li>EtOH levels may be negative unless acutely intoxicated</li>
</ul>
<h3 id="management_9">Management</h3>
<ul>
<li>
<p><strong>Supportive Care is essential!</strong> Consult nutrition, start high protein, high calorie diet, high dose Thiamine x 3d, Folate, MVI</p>
</li>
<li>
<p>Full infection workup (CXR, UA, BCx, paracentesis) regardless of symptoms</p>
</li>
</ul>
<h4 id="steroids">Steroids:</h4>
<ul>
<li>Discuss with hepatology team, &gt;20 clinical trials conducted with inconsistent results</li>
<li>Largest trial was the STOP-AH Trial (NEJM 2015) which showed improved mortality at 28 days in post hoc analysis, but not at 90 days in patients with Maddrey &gt; 32.</li>
<li>
<p>VA trial (patients with MDF &gt;54) showed increased mortality, indicating a possible ceiling at which point steroids may be harmful.</p>
</li>
<li>
<p>Individuals with a neutrophil: lymphocyte ratio of 5-8 are most likely to benefit from steroid use.</p>
</li>
<li>
<p>Treatment dose is <strong>prednisolone 40mg daily</strong> (preferred over prednisone as it requires hepatic metabolism)</p>
</li>
<li>
<p><strong>Contraindications to steroids include:</strong> presence of infection (must rule out first including TB, active Hep B, sepsis, uncontrolled GI bleeding, AKI w/ Cr &gt;2.5 mg/dL)</p>
</li>
<li>
<p>The <strong>Lille score</strong> can be used to assess response to steroids after 7 d of therapy and prognosticate mortality at 6 months</p>
</li>
<li>
<p>Lille&gt; 0.45 indicates no response to steroids and predicts 75% mortality at 6 months</p>
</li>
<li>
<p><strong>NAC</strong> should be considered as adjunctive therapy to steroids</p>
</li>
<li>
<p>Monitor on CIWA</p>
</li>
<li>Psychiatry consultation as appropriate, consideration of medical therapy (see "Substance Use Disorders" section in psychiatry)</li>
</ul>
<hr />
<h2 id="mash-and-masld">MASH and MASLD</h2>
<p><strong>Author: Shabnam Eghbali</strong></p>
<h3 id="background_12">Background</h3>
<ul>
<li><strong>Metabolic dysfunction-associated steatotic liver disease (MASLD)</strong> presence of hepatic steatosis (&gt;5% of hepatocytes with macro-vesicular steatosis) in the absence of secondary causes (e.g, EtOH or HCV GT3) and at least one of five of the below criteria:</li>
<li>BMI ≥ 25 OR waist circumference &gt; 94 cm (M) / 80 cm (F)</li>
<li>Fasting serum glucose ≥ 100 OR 2-hr post-load glucose levels ≥ 140 OR HgbA1c ≥ 5.7% OR T2DM</li>
<li>Blood pressure ≥ 130/85 OR on anti-hypertensive medication</li>
<li>Plasma triglycerides ≥ 150 OR on lipid lowering treatment</li>
<li>
<p>Plasma HDL ≤ 40 (M) / 50 (F) OR on lipid lowering treatment</p>
</li>
<li>
<p><strong>Metabolic dysfunction-associated steatohepatitis (MASH)</strong> evidence of active inflammation and cellular injury +/- fibrosis</p>
</li>
<li>
<p>Strong association with metabolic syndrome, T2DM, HTN, obesity</p>
</li>
<li>
<p>Prevalence of MASLD is 25-30% in general population and is now the leading cause of transplantation in American women</p>
</li>
</ul>
<h3 id="presentation_1">Presentation:</h3>
<ul>
<li>MASLD is asymptomatic and frequently found incidentally via imaging</li>
<li>MASH manifests with elevated liver enzymes, typically 2-5x the ULN, in a roughly 1:1 ratio (as opposed to alcoholic steatohepatitis), though ALT may be higher than AST. MASLD or MASH does NOT cause RUQ pain. Patients can still have normal liver enzymes with MASLD or MASH.</li>
</ul>
<h3 id="evaluation_12">Evaluation</h3>
<ul>
<li>Exclusion of alternative causes and comorbid liver conditions: HCV, HBV, EtOH, etc.</li>
<li>Screen for comorbid metabolic disorders: Lipid panel, hemoglobin a1c</li>
<li>
<p>Primary risk assessment with FIB-4 (see NITs section)</p>
</li>
<li>
<p>Diagnosis commonly made via imaging</p>
</li>
<li>US is used most frequently, although conventional B mode US lacks sensitivity for lower degrees of steatosis. As a result, controlled attenuation parameter (CAP) on VCTE (Ie FibroScan) is commonly used.</li>
<li>MRI is also acceptable. MRI-proton density fat fraction is a precise method for liver fat quantification (available for clinical care at VUMC)</li>
<li>Liver biopsy should be considered when non-invasive testing suggests significant fibrosis (≥F2)</li>
</ul>
<h3 id="management_10">Management</h3>
<ul>
<li>
<p>Aggressive risk factor modification and management of comorbidities (HLD, HTN, T2DM)</p>
</li>
<li>
<p><strong>Weight loss:</strong> Mediterranean diet&gt;low fat diet (dose dependent improvement), increased coffee consumption is associated with less progression of liver disease</p>
</li>
<li><strong>MASLD (fat only) Weight Loss Goal:</strong> &gt; 5% of body weight</li>
<li><strong>MASH (fat and inflammation) Weight Loss Goal:</strong> &gt;10% of body weight</li>
<li>
<p>Consider referral to weight loss clinic (BMI &gt;40, or &gt;35 with metabolic comorbidities)</p>
</li>
<li>
<p>Once the patient is diagnosed with MASLD, evaluation for fibrosis is indicated</p>
</li>
<li><strong>Fibrosis-4 (FIB 4) score:</strong> First line assessment. Assesses probability of fibrosis.</li>
<li>
<p><strong>Elastography:</strong> More accurate can be vibration based (fibroscan), US based (sheer-wave), or MR-based. Available at VUMC and can be ordered by anyone. Insurance will not cover MRE if BMI &lt;35</p>
<ul>
<li><strong>Fibroscan:</strong> &lt;10kPa r/o advanced chronic liver disease (fibrosis); 10-15kPa are suggestive of advanced chronic liver disease; &gt;15kPa are highly suggestive.</li>
</ul>
</li>
<li>
<p>Encourage etoh cessation; contributes to fatty liver disease progression</p>
</li>
<li>
<p>FDA recently approved <strong>Rezdiffra (resmetirom)</strong> for the treatment of adults with noncirrhotic MASLD with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise</p>
</li>
<li>
<p><strong>SGLT2 Inhibitors:</strong> May reduce steatosis in patients with MASLD+ DM</p>
</li>
<li>
<p><strong>Vitamin E:</strong> Can improve steatosis and inflammation in the setting of biopsy-proven MASH with evidence of hepatic fibrosis (fibrosis score 2+) in patients w/o DM</p>
</li>
<li>
<p><strong>GLP-1 agonists:</strong> Consider for patients with MASH+DM/obesity as it confers cardiovascular benefit and improves steatosis but probably not fibrosis</p>
</li>
<li>
<p><strong>GLP-1/GIP agonist (e.g, semaglutide) Tirzepatide):</strong> Can reduce steatosis. Can be use in patients with DM or obesity + NAFLD</p>
</li>
<li>
<p>Metformin, DPP4, statins, and silymarin are well studied in MASH and do not offer meaningful histologic benefit</p>
</li>
<li>In the pipeline: FGF21 agonists, THR beta agonists, PPAR agonists</li>
</ul>
<h3 id="additional-information">Additional Information</h3>
<ul>
<li>
<p><strong>Statins:</strong> should be used for HLD in pts with MASH, MASLD, and MASH cirrhosis</p>
</li>
<li>
<p>Statin use in decompensated MNASH cirrhosis is controversial, and they are less likely to derive benefit given overall poor prognosis, discontinue w/acute on chronic liver failure.</p>
</li>
</ul>
<hr />
<h2 id="acute-liver-injury-and-failure">Acute Liver Injury and Failure</h2>
<p><strong>Author: Wrinn Alexander</strong></p>
<h3 id="background_13">Background</h3>
<ul>
<li><strong>Acute liver injury (ALI):</strong> elevated liver enzymes + INR ≥1.5 without encephalopathy</li>
<li><strong>Acute liver failure (ALF):</strong> elevated liver enzymes + encephalopathy (any degree of AMS or asterixis) in the absence of pre-existing liver disease*</li>
<li>*Autoimmune hepatitis, HBV, Wilson disease, and Budd-Chiari syndrome can have ALF if they develop new AMS, despite the presence of a pre-existing liver disease</li>
<li><strong>Hyperacute (&lt; 7 d):</strong> most often seen with acetaminophen toxicity, Hepatitis A &amp; E, Ischemic; high risk for cerebral edema</li>
<li><strong>Acute (7-21 d):</strong> Hepatitis B</li>
<li>
<p><strong>Subacute (&gt; 21 d and &lt; 26 wk):</strong> most often non-acetaminophen DILI</p>
</li>
<li>
<p>Alcohol-associated hepatitis (AH) is not ALF (see above)</p>
</li>
<li>Duration of &lt;26 weeks is a commonly used cut-off</li>
</ul>
<h3 id="etiology">Etiology</h3>
<p><strong>R-factor</strong> (if history, exam, and diagnostic data are inconclusive i.e. R-factor is not a replacement to clinical judgement) = (ALT/uln ALT) / (ALP/uln ALP); See chart below
- R &gt; 5 = hepatocellular injury; R&lt;2 = cholestatic injury; R 2-5 = mixed injury</p>
<p><strong>Isolated hyperbilirubinemia:</strong> Differentiate direct versus indirect
- <strong>Direct:</strong> Refer to cholestatic pattern
- <strong>Indirect:</strong> Gilbert vs. hemolysis</p>
<h4 id="drugs-associated-with-liver-injury">Drugs Associated with liver injury:</h4>
<ul>
<li>
<p><strong>Hepatocellular pattern:</strong> acarbose, Acetaminophen, Allopurinol, Amiodarone, Baclofen, Bupropion, Fluoxetine, HAART (Nevirapine), Kava kava, Isoniazid, Ketoconazole, Lisinopril, Losartan, Methotrexate, NSAIDs, Omeprazole, Oxacillin/Nafcillin, Paroxetine, Pyrazinamide, Propylthiouracil, Rifampin, Risperidone, Sertraline, Statins, Tetracycline, Trazodone, Valproic Acid</p>
</li>
<li>
<p><strong>Mixed pattern:</strong> Amitriptyline, Azathioprine, Captopril, Carbamazepine, Clindamycin, Cyproheptadine, Enalapril, Flutemide, Nitrofurantoin, Phenobarbital, Phenytoin, Sulfonamides, Trazodone, Verapamil</p>
</li>
<li>
<p><strong>Cholestatic pattern:</strong> Amoxicillin-clavulanic acid, Anabolic steroids, Chlorpromazine, Clopidogrel, Oral contraceptives, Erythromycins, Estrogens, Irbesartan, Mirtazapine, Phenothiazines, Terbinafine, Tricyclics</p>
</li>
</ul>
<h3 id="hepatocellular-injury-r-factor-5-primary-elevation-of-astalt">Hepatocellular Injury: R factor &gt; 5 (Primary elevation of AST/ALT)</h3>
<table>
<thead>
<tr>
<th>Etiology</th>
<th>Description</th>
<th>Work Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overdose/Toxins$</td>
<td>Acetaminophen, ASA, alcohol, cocaine, mushrooms (Amanita phalloides)</td>
<td>Acetaminophen, ethanol level, Peth, UDS</td>
</tr>
<tr>
<td>Acute Viral Hepatitis</td>
<td>Hep A$, B<em>$, C</em>, D, E; EBV, CMV, HSV, VZV</td>
<td>Viral serologies and PCR</td>
</tr>
<tr>
<td>Autoimmune hepatitis*</td>
<td>Presence of circulating autoantibodies and a high serum globulin concentration</td>
<td>Anti-smooth muscle (f-actin), ANA, ANCA, anti-liver kidney microsome (anti-LKM-1), anti-soluble liver antigen/liver-pancreas IgG</td>
</tr>
<tr>
<td>Budd-Chiari Syndrome*</td>
<td>Hepatic vein obstruction</td>
<td>Ultrasound of abdomen w/ doppler, CT w/ contrast</td>
</tr>
<tr>
<td>DILI – Drug Induced Liver Injury*$</td>
<td>Dose independent (NOT an overdose)</td>
<td>Review patient's med list with NIH Liver Tox Database: https://www.livertox.nih.gov</td>
</tr>
<tr>
<td>HELLP Syndrome, Acute Fatty Liver of Pregnancy</td>
<td>HELLP: A severe form of preeclampsia; AFLP: defects in fatty acid metabolism during pregnancy</td>
<td>Check bHCG in females of reproductive age</td>
</tr>
<tr>
<td>Ischemic Liver Injury (Shock Liver)$</td>
<td>Shock (can be of any variety)</td>
<td>AST &gt; ALT can be in the thousands, high LDH, history of hypotension, UDS to eval for vasoconstrictive drugs</td>
</tr>
<tr>
<td>Wilson's Disease*</td>
<td>Mutation in ATP7B, gene for copper transport protein, leads to accumulation of copper in liver and other organs</td>
<td>Ceruloplasmin level (screening), 24h urine copper (confirmation), quantitative copper on liver biopsy. Genetic testing</td>
</tr>
</tbody>
</table>
<p>*May present with chronic liver injury as well; $May present with AST/ALT &gt;100</p>
<h3 id="cholestatic-injury-r-factor-2-primarily-elevated-alkaline-phosphatase">Cholestatic Injury: R Factor &lt; 2 (Primarily elevated Alkaline phosphatase)</h3>
<table>
<thead>
<tr>
<th>Etiology</th>
<th>Description</th>
<th>Work Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute biliary obstruction</td>
<td>Choledocholithiasis</td>
<td>Abdominal ultrasound, MRCP, ERCP</td>
</tr>
<tr>
<td>DILI – Drug-induced liver injury*$</td>
<td>Dose independent (NOT an overdose)</td>
<td>Review patient's med list. Refer to Liver Tox Database: https://www.livertox.nih.gov Common: Augmentin, Bactrim, amiodarone, Imuran</td>
</tr>
<tr>
<td>Malignancy*</td>
<td>Pancreatic malignancy, cholangiocarcinoma</td>
<td>CT abdomen, ERCP</td>
</tr>
<tr>
<td>Primary Biliary Cirrhosis*</td>
<td>Autoimmune</td>
<td>AMA, ALP. If AMA + and ALP &gt;225 meets diagnostic criteria. If only one positive, will need liver biopsy.</td>
</tr>
<tr>
<td>Primary Sclerosing Cholangitis*</td>
<td>Autoimmune, associated with IBD</td>
<td>MRCP, ERCP</td>
</tr>
<tr>
<td>Critical illness or COVID cholangiopathy</td>
<td>Hypotension, COVID</td>
<td>MRCP with biliary stenosis, appropriate history</td>
</tr>
</tbody>
</table>
<p>*May present with chronic liver injury as well; $May present with AST/ALT &gt;100</p>
<h3 id="evaluation_13">Evaluation</h3>
<h4 id="neurologic-exam">Neurologic Exam:</h4>
<ul>
<li>See Hepatic Encephalopathy section for grading of HE based on PE/Hx</li>
<li><strong>Grade I and II HE:</strong> cerebral edema uncommon</li>
<li><strong>Grade III HE:</strong> Cerebral Edema in 25-35% of patients</li>
<li>
<p><strong>Grade IV HE:</strong> Cerebral Edema in 75% of patients</p>
</li>
<li>
<p><strong>Signs of increased intracranial pressure:</strong></p>
</li>
<li>
<p>Pupillary changes, Cushing's triad (HTN, bradycardia, respiratory depression, seizures, increased muscle tone and hyperreflexia, abnormal brainstem reflexes</p>
</li>
<li>
<p><strong>Consult hepatology once you suspect ALF!</strong> (to assist with workup AND for transplant evaluation)</p>
</li>
</ul>
<h4 id="labs_1">Labs:</h4>
<ul>
<li>CBC w/diff, CMP, Dbili, Mg, Phos, T&amp;S, BCx, UCx, PT/INR, aPTT, fibrinogen</li>
<li>Ferritin, Iron, transferrin (HFE gene mutation testing if Tsat ≥45% and/or elevated ferritin)</li>
<li>Amylase, lipase</li>
<li>Beta-hCG for females of childbearing age; UA to assess for proteinuria if pregnant</li>
<li>ABG with arterial lactate, ammonia (arterial &gt;124 predicts mortality and CNS complications e.g., need for intubation, seizures, cerebral edema, &lt;75 very unlikely to develop ICH)</li>
<li><strong>Viral etiologies:</strong> Viral hepatitis serologies (HAV panel, HBV panel, HCV IgG +/- PCR quant, HDV if known HBV (with low or undetectable HBV load) as Misc Reference Test, Hepatitis E PCR sent as miscellaneous if pregnant or travel to southeast Asia), HIV p24 Ag and HIV Ab, EBV Qt, CMV Qt, HSV 1/2, Qt, VZV IgM/IgG</li>
<li><strong>Toxins:</strong> UDS, ethanol level +/- Peth, acetaminophen level (drawn ≥4 hours after last known ingestion), salicylate level</li>
<li><strong>Autoimmune/genetic:</strong> ANA, ASMA, IgG, AMA (if predominantly elevated ALP), ceruloplasmin, anti-liver/kidney microsomal antibody type 1, anti-liver soluble antigen, alpha-1 antitrypsin</li>
<li>*You may not order all the workup included above; hepatology will guide you on what exactly will need to be ordered.</li>
</ul>
<h4 id="imaging_1">Imaging:</h4>
<ul>
<li>RUQ U/S with doppler (important to assess vasculature!)</li>
<li>Consider CT with contrast in patients with normal renal function and high suspicion of Budd-Chiari syndrome or malignancy with negative ultrasound (better for assessing the hepatic veins) and helps with transplant evaluation</li>
<li>Consider TTE to assess for cardiac dysfunction and aid in transplantation consideration</li>
<li>Consider CTH or MRI to assess for cerebral edema (findings include decrease in ventricular size, flattening of cerebral convolutions, reduction in signal intensity of brain parenchyma)</li>
<li>
<p>Consider ERCP/MRCP for cholestatic etiologies</p>
</li>
<li>
<p>Discuss possible <strong>liver biopsy</strong> if etiology unclear</p>
</li>
<li>Transjugular approach preferred with clinically demonstrable ascites; a known or suspected hemostatic defect; a small, hard, cirrhotic liver; morbid obesity with a difficult-to-identify flank site; or those in whom free and wedged hepatic vein pressure measurements are additionally being sought.</li>
</ul>
<h3 id="management_11">Management</h3>
<ul>
<li>
<p>Any pt with concern for ALF should be cared for in MICU (even if mild change in mental status)</p>
</li>
<li>
<p>Pts with ALF may die acutely from hypoglycemia, cerebral edema, and infection</p>
</li>
</ul>
<h4 id="abcs">ABC's:</h4>
<ul>
<li>Intubate for GCS &lt;8, Grade 3 or 4 HE</li>
<li>IVF resuscitation with isotonic crystalloid (most pts are volume deplete; avoid hypotonic fluids due to risk of cerebral edema)</li>
<li>Vasopressive agents for persistent hypotension (norepinephrine is the preferred agent, addition of vasopressin and stress dose steroids may be warranted)</li>
</ul>
<h4 id="monitoring">Monitoring:</h4>
<ul>
<li>Q1-2h neuro checks, Q1-2h glucose checks</li>
<li>Closely monitor CMP, Magnesium, phosphorus, INR q6-8 hrs</li>
</ul>
<h3 id="treatment-of-primary-injury">Treatment of Primary Injury</h3>
<ul>
<li>
<p>Early hepatology consult for liver transplant evaluation and assistance in management</p>
</li>
<li>
<p><strong>IV N-acetylcysteine:</strong> May improve transplant-free survival even in patients WITHOUT non-acetaminophen drug induced acute liver failure</p>
</li>
<li>Initial loading dose = 150mg/kg over 1 hour, then 50mg/kg/hr for 4 hours, then 100mg/kg/hr for 16 hours</li>
<li>Patients with early-stage hepatic encephalopathy (grade I/II) have increased transplant free survival, while those with grade III/IV do not</li>
</ul>
<h3 id="treatment-of-secondary-complications">Treatment of Secondary Complications</h3>
<ul>
<li>
<p><strong>Infection:</strong> Rule out infection with CXR, Blood cultures, UA/UCx for every ALF. Antibiotics only if progressing HE, signs of infection, or development of SIRS</p>
</li>
<li>
<p><strong>Cerebral edema/increased ICP:</strong></p>
</li>
<li>No role for lactulose in the setting of acute liver failure</li>
<li><strong>Grade III-IV hepatic encephalopathy:</strong> elevated HOB to 30 degrees, quiet and dimly lit room, should be intubated, avoid sedating medications as feasible, and ICP monitor are recommended (if not feasible, hourly neuro checks can be an alternative). If ICP becomes elevated start targeted therapies to reduce intracranial pressure.</li>
<li>Mannitol or hypertonic saline should be administered for surges of ICP with consideration for short-term hyperventilation</li>
<li>
<p>If high ICP is refractory to osmotic agents, consider phenobarbital, indomethacin, and/or cooling to 33-34 degrees Celsius if awaiting LT</p>
</li>
<li>
<p><strong>Seizures:</strong> phenytoin (no evidence to support seizure ppx), short acting benzodiazepines if refractory</p>
</li>
<li>
<p><strong>Renal Failure:</strong> early CRRT if persistent metabolic acidosis, volume overload, falling UOP</p>
</li>
<li>
<p><strong>Coagulopathy:</strong> IV Vit K (at least one dose) routinely to rule out Vit K deficiency, products for invasive procedures or active bleeding only</p>
</li>
<li>
<p>If trying to differentiate from DIC, can order Factor VIII level (should be normal/high in ALF; low in DIC)</p>
</li>
<li>
<p><strong>Metabolic:</strong> Correction of hypoglycemia (continuous D20) and electrolyte abnormalities</p>
</li>
<li>
<p><strong>Circulatory dysfunction/shock:</strong> Goal MAP &gt;75 mmHg. Ensure intravascularly replete, add norepinephrine first line, vasopressin can be used second line but may increase ICP. Consider stress dose steroids for refractory shock</p>
</li>
<li>
<p><strong>Additional Supportive Care</strong></p>
</li>
<li>PPI for bleeding ppx</li>
<li>Enteral nutrition EARLY; avoid TPN if possible</li>
<li>Prefer propofol for sedation for better neuro exams and may reduce cerebral blood flow</li>
</ul>
<h3 id="specific-management-by-etiology">Specific Management by Etiology:</h3>
<ul>
<li><strong>Acetaminophen</strong></li>
<li>Early toxicology consultation if suspected ingestion/overdose</li>
<li>For acute management contact Poison Control 800-222-1222</li>
<li>Activated charcoal within 4 hours of ingestion, most effective within 1 hour</li>
<li>
<p>IV N-acetylcysteine per protocol, look up Rumack-Mattew Nomogram and consult with toxicology</p>
<ul>
<li>In Epic: search "N-acetylcysteine" and select order set "Acetaminophen overdose"</li>
</ul>
</li>
<li>
<p><strong>AFLP/HELLP</strong> – delivery</p>
</li>
<li><strong>Amanita phalloides</strong> – IV fluid resuscitation, PO charcoal, IV penicillin, IV acetylcysteine</li>
<li><strong>Autoimmune</strong> – IV steroids following approval by hepatology (and typically post biopsy). Azathioprine generally deferred until cholestasis resolved (Mycophenolate can be used instead)</li>
<li><strong>Budd-Chiari</strong> – anticoagulation, IR-guided endovascular therapy, transplant (must rule out underlying malignancy and evaluate for thrombotic disorders)</li>
<li><strong>HAV/HEV</strong> – supportive care, consider ribavirin for ALF due to HEV</li>
<li><strong>HBV</strong> – nucleos(t)ide analogue; orthotopic liver transplant</li>
<li><strong>HSV</strong> – acyclovir, consider administering prophylactically until excluded based on lab work</li>
</ul>
<h3 id="criteria-for-transplantation">Criteria for Transplantation:</h3>
<p><strong>King's College criteria:</strong> helps identify patients needing transplant referral/consideration</p>
<h4 id="a-alf-due-to-acetaminophen">A) ALF due to acetaminophen:</h4>
<ul>
<li>Arterial pH &lt;7.3 after resuscitation and &gt;24 hr since ingestion, OR</li>
<li>Arterial lactate &gt;3 after adequate fluid resuscitation, OR</li>
<li>Grade III- IV HE, and SCr &gt;3.4, and INR &gt;6.5 all within 24h period</li>
</ul>
<h4 id="b-alf-not-due-to-acetaminophen-inr-65-or-3-of-the-5-following-criteria">B) ALF not due to acetaminophen: INR &gt; 6.5 OR 3 of the 5 following criteria:</h4>
<ul>
<li>Etiology: Indeterminate etiology, idiosyncratic drug- induced hepatitis</li>
<li>Age &lt;10 or &gt;40</li>
<li>Interval of jaundice to onset of encephalopathy &gt;7 days</li>
<li>Bilirubin &gt; 17.5mg/dl (300mmol/L)</li>
<li>INR &gt;3.5</li>
</ul>
<h4 id="other-predictors-of-poor-prognosis-in-absence-of-transplant">Other predictors of poor prognosis in absence of transplant:</h4>
<ul>
<li><strong>Hyperlactatemia:</strong> lactate &gt;3.5 after 4 hours of IVF or &gt;3 after 12 hours IVF</li>
<li><strong>Hyperphosphatemia:</strong> Phosphate &gt;3.75 at 48-96 hours</li>
</ul>
<hr />
<h2 id="non-invasive-liver-testing-for-liver-disease">Non-Invasive Liver Testing for Liver Disease</h2>
<p><strong>Author: Shabnam Eghbali</strong></p>
<h3 id="evaluation_14">Evaluation</h3>
<ul>
<li>
<p><strong>Who should be evaluated:</strong> patients with steatosis noted on imaging or for whom there is a clinical suspicion of MASLD, such as those with metabolic risk factors (e.g., HTN, HLD, T2DM, obesity) or unexplained elevations in liver chemistries</p>
</li>
<li>
<p><strong>Primary risk assessment for MASLD → FIB-4</strong> – estimates degree of scarring and is based on age, AST, ALT, platelet count; high negative predictive value to exclude advanced fibrosis (F3-4); less reliable in patients under the age of 35 or over the age of 65</p>
</li>
<li>
<p><strong>If FIB-4 &lt;1.3</strong> → reassess periodically</p>
<ul>
<li>Every 1-2 years if T2DM/pre-T2DM or ≥2 metabolic risk factors</li>
<li>Every 2-3 years if no T2DM and &lt;2 metabolic risk factors</li>
</ul>
</li>
<li>
<p><strong>If FIB-4 ≥ 1.3</strong> → secondary risk assessment with elastography Vibration-controlled transient elastography (VCTE) also known as FibroScan if BMI &lt; 35 or MR elastography if BMI &gt; 35)</p>
<ul>
<li><strong>Low risk</strong> = VCTE &lt;8 kilopascal, MRE without significant fibrosis (F2-4), reassess periodically</li>
<li><strong>Intermediate/high risk</strong> = VCTE &gt;8, MRE F2-4 → referral to Hepatology</li>
</ul>
</li>
<li>
<p><strong>If FIB-4 &gt; 2.67</strong> → immediate referral to Hepatology</p>
</li>
<li>
<p><strong>Secondary risk assessment for MASLD</strong> → (VCTE), also known as FibroScan, which provides following measurements:</p>
</li>
<li>
<p><strong>CAP score (dB/m)</strong> → rough estimate of steatosis with relatively limited reliability</p>
<ul>
<li>238 – 260 → S1 (less 1/3 of liver affected by fatty change)</li>
<li>260 – 290 → S2 (between 1/3 and 2/3 of liver affected by fatty change)</li>
<li>290 – 400 → S3 (mor than 2/3 of liver affected by fatty change)</li>
</ul>
</li>
<li>
<p><strong>Liver stiffness (LSM) (kPa)</strong> → fibrosis score … ranges differ based on underlying liver disease but approximately,</p>
<ul>
<li>2 – 7 → F0 to F1</li>
<li>8 – 11 → F2</li>
<li>11 – 14 → F3</li>
<li>14 or higher → F4</li>
</ul>
</li>
<li>
<p><strong>Limitations to VCTE:</strong> not available at all centers, significant central adiposity that interferes with measurements, cardiac device not amenable to use of VCTE</p>
</li>
<li>
<p><strong>AGILE 3+</strong> – a recently developed score based on combination of AST/ALT ratio, platelet count, diabetes, sex, age, LSM</p>
</li>
</ul>
<h4 id="shear-wave-elastography-interpretation">Shear wave elastography interpretation:</h4>
<ul>
<li>≤ 5 kPa → high probability of being normal</li>
<li>&lt; 9 kPa → In the absence of other known clinical signs, rule out compensated advanced liver disease (cACLD). If there are known clinical signs, may need further test for confirmation</li>
<li>9-13 kPa suggestive of cACLD but need further test for confirmation</li>
<li>
<blockquote>
<p>13 kPa Rules in cACLD</p>
</blockquote>
</li>
<li>
<blockquote>
<p>17 kPa suggestive of clinically significant portal hypertension</p>
</blockquote>
</li>
</ul>
<hr />
<p><em>Page 248-272</em></p>
              
            </div>
          </div><footer>
    <div class="rst-footer-buttons" role="navigation" aria-label="Footer Navigation">
        <a href="../Hematology%20and%20Oncology/" class="btn btn-neutral float-left" title="Hematology and Oncology"><span class="icon icon-circle-arrow-left"></span> Previous</a>
        <a href="../Hospital%20Medicine/" class="btn btn-neutral float-right" title="Hospital Medicine">Next <span class="icon icon-circle-arrow-right"></span></a>
    </div>

  <hr/>

  <div role="contentinfo">
    <!-- Copyright etc -->
  </div>

  Built with <a href="https://www.mkdocs.org/">MkDocs</a> using a <a href="https://github.com/readthedocs/sphinx_rtd_theme">theme</a> provided by <a href="https://readthedocs.org">Read the Docs</a>.
</footer>
          
        </div>
      </div>

    </section>

  </div>

  <div class="rst-versions" role="note" aria-label="Versions">
  <span class="rst-current-version" data-toggle="rst-current-version">
    
    
      <span><a href="../Hematology%20and%20Oncology/" style="color: #fcfcfc">&laquo; Previous</a></span>
    
    
      <span><a href="../Hospital%20Medicine/" style="color: #fcfcfc">Next &raquo;</a></span>
    
  </span>
</div>
    <script src="../js/jquery-3.6.0.min.js"></script>
    <script>var base_url = "..";</script>
    <script src="../js/theme_extra.js"></script>
    <script src="../js/theme.js"></script>
      <script src="../search/main.js"></script>
    <script>
        jQuery(function () {
            SphinxRtdTheme.Navigation.enable(true);
        });
    </script>

</body>
</html>
